Genetic mutations coupled with environmental factors can lead to the development of cancer, including mesothelioma. Some of those mutations have prognostic implications, while others may help doctors determine which therapies will effect a response in a particular patient.
This session was presented at the 2023 International Symposium on Malignant Mesothelioma in Washington, DC, and featured:
Alexandra Lebensohn, MS, CGC, NCI
Azam Ghafoor, MD, NCI
This is a recording of a session at the 2023 International Symposium on Malignant Mesothelioma. This symposium is made possible by our generous sponsors: Belluck and Fox, LLP; Maune Raichle Hartley French & Mudd, LLC (MRHFM); Polaris Pharmaceuticals, Inc.; Bristol Myers Squibb; Merck; The Gori Law Firm; Ikena Oncology; Early Lucarelli Sweeney & Meisenkothen; Novacure
Find other recorded sessions and more information at www.curemeso.org/symposium
